Innate immunity in heart transplantation
Authors:
- 1 October 2009
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 14 (5) , 571-576
Abstract
Purpose of review Cardiac transplantation is the treatment of choice for end-stage heart failure, but its efficacy is limited by the development of cardiac allograft vasculopathy (CAV). Although the adaptive immune system is efficiently suppressed by conventional drugs, the innate immune system is largely unaffected. The innate response may contribute both to stimulation of the adaptive response and to the future development of CAV. Recent findings Stimulation of Toll-like receptors by endogenous ligands released in response to ischemia/reperfusion causes an inflammatory milieu favorable to graft rejection and unfavorable to tolerance. New evidence suggests that natural killer cells have previously unknown memory-like features and are capable of graft rejection. Their role in rejecting the cardiac allograft has previously been underestimated. Complement deposition may also contribute to acute cellular rejection and CAV. Summary The innate immune system is an important but neglected component of allograft rejection. Drugs that target Toll-like receptors, natural killer cells and complement may play an important role in preventing CAV and achieving tolerance to cardiac allografts.Keywords
This publication has 34 references indexed in Scilit:
- Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heartAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Mechanisms Underlying Blockade of Allograft Acceptance by TLR LigandsThe Journal of Immunology, 2008
- High-Mobility Group Box-1 in Ischemia-Reperfusion Injury of the HeartCirculation, 2008
- Critical role of extracellular heat shock cognate protein 70 in the myocardial inflammatory response and cardiac dysfunction after global ischemia-reperfusionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Cardiac Allograft VasculopathyCirculation, 2008
- Activation of the innate immune system by the endogenous ligand hyaluronanCurrent Opinion in Organ Transplantation, 2008
- Toll-like receptor 3 is an essential component of the innate stress response in virus-induced cardiac injuryAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- 329The Journal of Heart and Lung Transplantation, 2006
- mRNA Is an Endogenous Ligand for Toll-like Receptor 3Journal of Biological Chemistry, 2004
- Peritransplant Injury to the Myocardium Associated with the Development of Accelerated Arteriosclerosis in Heart Transplant RecipientsAmerican Journal of Surgical Pathology, 1994